AC Immune (ACIU) director Zuegel reports options and RSU-based share stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
AC Immune SA director Martin Zuegel filed an initial ownership report showing equity interests in the company. He holds share options over 52,577 and 32,061 common shares, each with an exercise price of $1.8400 per share and an expiration date of June 17, 2035. One option grant will fully vest on June 17, 2026, while the other will vest annually in three equal installments beginning on June 17, 2026. He also directly holds 38,272 common shares, which reflect common shares underlying outstanding restricted share units.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Zuegel Martin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Common Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 52,577 shares (Direct);
Common Shares — 38,272 shares (Direct)
Footnotes (1)
- Reflects common shares underlying outstanding restricted share units. The share option will fully vest on June 17, 2026. The share option will vest annually in three equal installments beginning on June 17, 2026.
Key Figures
Common shares held: 38,272 shares
Option underlying shares (grant 1): 52,577 shares
Option underlying shares (grant 2): 32,061 shares
+4 more
7 metrics
Common shares held
38,272 shares
Direct common shares reflecting RSU-based holdings as of Form 3
Option underlying shares (grant 1)
52,577 shares
Share option over common shares, exercise price $1.8400, expires June 17, 2035
Option underlying shares (grant 2)
32,061 shares
Share option over common shares, exercise price $1.8400, expires June 17, 2035
Option exercise price
$1.8400 per share
Exercise price for both reported share option positions
Option expiration date
June 17, 2035
Expiration date for both share option grants
Full vesting date (grant 1)
June 17, 2026
Share option that will fully vest on this date
Start of annual vesting (grant 2)
June 17, 2026
Share option vesting annually in three equal installments beginning this date
Key Terms
Share Option (right to buy), restricted share units, expiration date, vest annually in three equal installments, +1 more
5 terms
expiration date financial
"expiration_date: "2035-06-17T00:00:00.000Z" for the share options"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest annually in three equal installments financial
"The share option will vest annually in three equal installments beginning on June 17, 2026."
beneficial ownership financial
"These positions reflect his initial beneficial ownership as a director."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
What equity holdings does AC Immune (ACIU) director Martin Zuegel report on this Form 3?
Martin Zuegel reports direct ownership of 38,272 common shares and two share option positions over 52,577 and 32,061 common shares. These positions reflect his initial beneficial ownership as a director of AC Immune SA.